Management of relapsed-refractory diffuse large B cell lymphoma. - Wikidata - awgldk - TriplyDB

Management of relapsed-refractory diffuse large B cell lymphoma.

Management of relapsed-refractory diffuse large B cell lymphoma.

http://www.wikidata.org/entity/Q37654010

about

Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity.PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma.Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo.A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.Current Progress in EBV-Associated B-Cell Lymphomas.Chimeric Antigen Receptor T-Cell Therapy for Lymphomas.The fear of lymphadenopathy: A cautionary case of sarcoidosis masquerading as recurrent diffuse large b-cell lymphoma (DLBCL).Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: a systematic review.Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group

P2860

Q33622342-A7E87F17-B9FB-4C36-A4BC-E0907B8D4C64 Q33758660-802498F0-347C-4825-A467-13F9AA0A9043 Q34293322-C11DBC64-5572-47EA-9554-CD1033777C16 Q37429917-CE88C028-1388-4BFA-9924-C408752221AA Q37589543-6E2D2E22-73D0-4F6E-AA40-277737BADE7F Q38836263-0F45224E-B1BB-4B06-839F-6767A7AEBAA4 Q41385777-D58C4340-9C5A-4C16-A9A4-7B37CE086F72 Q47606345-03366276-03D9-4191-B354-0A1F30CAF940 Q48558501-78E89BC9-0804-45E9-9D0C-D03E5D03E0D1 Q55024881-AED9B8AF-3A04-4D76-BD05-B0BD6AEBE308 Q55119635-36077D34-0611-4867-BEFF-247C6E5E8E66 Q58801965-9C37E223-43F2-4961-BECF-0F8B8AD67CF0

P2860

Management of relapsed-refractory diffuse large B cell lymphoma.

http://www.wikidata.org/entity/Q37654010

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Management of relapsed-refractory diffuse large B cell lymphoma.

@en

Management of relapsed-refractory diffuse large B cell lymphoma.

@nl

type

label

Management of relapsed-refractory diffuse large B cell lymphoma.

@en

Management of relapsed-refractory diffuse large B cell lymphoma.

@nl

prefLabel

Management of relapsed-refractory diffuse large B cell lymphoma.

@en

Management of relapsed-refractory diffuse large B cell lymphoma.

@nl

P1433

Q37654010-6F465569-3E84-4C49-8026-9F8A86681147

P1476

Q37654010-5B7CEE52-48C8-4548-A577-53495C19BCED

P2093

Q37654010-0F043366-3CD5-4FFF-8305-2D48C735C1EC

Q37654010-918A390A-7603-4980-9FE4-2781077FD70B

P2860

Q37654010-03451DF9-A000-4646-93F1-059268428ABC

Q37654010-0C4AFA56-8D4A-4AB1-BC7D-D34C80F7DD60

Q37654010-142A866F-FB51-45F8-87F7-2E976CE870B2

Q37654010-1533CB52-164D-4D65-8180-609569ADD4E2

Q37654010-161EF184-66AB-4DC9-BA80-F378B3D2C48D

Q37654010-1C79BF2C-9A9B-4DAC-AA29-671D6591EA82

Q37654010-22F5D28E-50BF-405F-82E7-2D533575F928

Q37654010-252D4BA6-E4C7-472C-AE76-0CC9E1F85043

Q37654010-2B25665F-9547-4854-A237-6FE821C5CCD0

Q37654010-32EA6A4C-F35C-49E8-ADB0-5BD3346848A3

P304

Q37654010-2775A1E9-747A-4198-86FF-0F1AE089BDA5

P31

Q37654010-4E89560F-FBE6-4D26-BFD0-FDDE176E9AA7

P356

Q37654010-B69ABDA4-7FD7-4146-97F0-A38712F2BF00

P433

Q37654010-C8D4FAE7-BD5B-4C05-869D-F5F6AF99788C

P478

Q37654010-8DC9B8A7-EBE1-4EEF-8A7C-7B8422C12E3D

P577

Q37654010-5275D8DA-64EE-498A-A4DF-14FBF5D4D705

P698

Q37654010-3C50B3DB-56DB-4A63-A7F8-85B319B985BE

P921

Q37654010-E0768C6B-C2BD-46B3-969F-14E4215D8CCE

P932

Q37654010-8003041E-1AA7-4BBA-BD15-D7D25D0B7997

P356

2278-330X.126531

P1433

South Asian Journal of Cancer

P1476

Management of relapsed-refractory diffuse large B cell lymphoma.

@en

P2093

Lalit S Raut

http://www.w3.org/2001/XMLSchema#string

Prantar P Chakrabarti

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Aggressive lymphomas

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Stromal gene signatures in large-B-cell lymphomas

Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.

Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.

P304

66-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2278-330X.126531

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24665451

http://www.w3.org/2001/XMLSchema#string

P921

relapsed/refractory diffuse large B-cell lymphoma

P932

3961873

http://www.w3.org/2001/XMLSchema#string